Literature DB >> 16359194

CTX-M-1 extended-spectrum beta-lactamase-producing Proteus mirabilis in Greece.

Paraskevi Karapavlidou1, Danai Sofianou, Evangelos N Manolis, Spyros Pournaras, Athanassios Tsakris.   

Abstract

To examine the dissemination of CTX-M-type extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Proteus mirabilis, 91 nonrepetitive ESBL-producing P. mirabilis were collected from infected patients in a tertiary Greek hospital during September, 2001, to May, 2004. A bla (CTX-M) gene was amplified in one isolate (strain A328), but bla (CTX-M) was not detected in any of the remaining ESBL producers. Sequencing results showed that P. mirabilis A328 produced a CTX-M-1 enzyme while PCR mapping of the genetic element carrying bla (CTX-M-1) revealed that the gene was located downstream of an ISEcp1B element. The cefotaxime resistance determinant was easily transferable and carried on a 70-kb plasmid. The emergence of CTX-M-1- producing P. mirabilis indicates the need for early recognition of such strains to be able to control their spread in our hospital and community environment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16359194     DOI: 10.1089/mdr.2005.11.351

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  2 in total

1.  Characterization of CTX-M-140, a Variant of CTX-M-14 Extended-Spectrum β-Lactamase with Decreased Cephalosporin Hydrolytic Activity, from Cephalosporin-Resistant Proteus mirabilis.

Authors:  Guo-Bao Tian; Yi-Qi Jiang; Ying-Min Huang; Yun Qin; Lian-Qiang Feng; Xue-Fei Zhang; Hong-Yu Li; Lan-Lan Zhong; Kun-Jiao Zeng; Sandip Patil; Yong Xing; Xi Huang
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Trends of mortality due to septicemia in Greece: an 8-year analysis.

Authors:  Matthew E Falagas; Ioanna P Korbila; Anastasios Kapaskelis; Kyriaki Manousou; Lili Leontiou; Giannoula S Tansarli
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.